Economic Toxicities and MPN

Ruben Mesa, MD of the Mayo Clinic in Scottsdale, AZ talks about the data he presented at the 58th Annual ASH Meeting & Exposition showing that half of teh patients with myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia end up having a change in their employment status following their diagnosis (eg, leaving job, medical disability leave, early retirement) that they attributed to their disease.

Reference
Yu J, Parasuraman S, Paranagama D, et al. Impact of Myeloproliferative Neoplasms on Patients’ Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey. Presented at the 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016. Abstract 4256.